The purpose of the Board is to serve as a forum for regular and direct communication between The Endocrine Society and the pharmaceutical and biotechnology industry in endocrinology. The newly created Board is comprised of nine companies, ranging in size and scope of practice.
Membership rotates every three years.
The Forum was an opportunity to introduce the concept of the Board to Endocrine Society membership and members of industry, and to allow them an opportunity to provide feedback on important issues to which the CLB should focus its attention in the near future. A presentation about The Endocrine Society's members, and the creation of the CLB was made by Endocrine Society Executive Director, Mr. Scott Hunt and Corporate Liaison Board Chair, Dr. Elizabeth Stoner, respectively. Together, The Endocrine Society and the CLB will work to ensure continued collaboration between doctors of endocrinology and pharmaceutical and biotechnological industry to provide the best communication and information to patients. As a team, these two groups will work to become a unified voice for the endocrine field. .